Stock Track | Twist Bioscience Soars 5.16% Intraday After Q3 Revenue Beat, Raised FY Guidance, and EBITDA Breakeven Outlook

Stock Track08-03

Twist Bioscience Corp. (TWST) shares surged 5.16% during intraday trading on Monday, as investors reacted positively to the company's fiscal third-quarter 2026 earnings release, which delivered a top-line beat, raised full-year guidance, and a clear path to adjusted EBITDA breakeven.

The company reported Q3 FY26 revenue of $118.4 million, up 23% year-over-year and comfortably above the FactSet consensus estimate of $114.5 million. Gross margin improved to 52.8%, while the adjusted EBITDA loss narrowed to $11.3 million. Management also raised its full-year fiscal 2026 revenue guidance to a range of $456 million to $457 million, up from the prior $442 million to $447 million, and projected fourth-quarter revenue of approximately $123 million to $124 million, well ahead of the $117.4 million consensus.

Adding to the bullish sentiment, Twist Bioscience said it expects to achieve adjusted EBITDA breakeven in the fiscal fourth quarter and sees full-year gross margins above 52%. The combination of accelerating revenue growth, margin expansion, and a near-term profitability milestone fueled the sharp intraday rally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1198645126?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-03 22:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198645126","market":"sg","top_or_hot":-1,"title":"Stock Track | Twist Bioscience Soars 5.16% Intraday After Q3 Revenue Beat, Raised FY Guidance, and EBITDA Breakeven Outlook","media":"Stock Track","content":"<p>Twist Bioscience Corp. (TWST) shares surged 5.16% during intraday trading on Monday, as investors reacted positively to the company's fiscal third-quarter 2026 earnings release, which delivered a top-line beat, raised full-year guidance, and a clear path to adjusted EBITDA breakeven.</p><p>The company reported Q3 FY26 revenue of $118.4 million, up 23% year-over-year and comfortably above the FactSet consensus estimate of $114.5 million. Gross margin improved to 52.8%, while the adjusted EBITDA loss narrowed to $11.3 million. Management also raised its full-year fiscal 2026 revenue guidance to a range of $456 million to $457 million, up from the prior $442 million to $447 million, and projected fourth-quarter revenue of approximately $123 million to $124 million, well ahead of the $117.4 million consensus.</p><p>Adding to the bullish sentiment, Twist Bioscience said it expects to achieve adjusted EBITDA breakeven in the fiscal fourth quarter and sees full-year gross margins above 52%. The combination of accelerating revenue growth, margin expansion, and a near-term profitability milestone fueled the sharp intraday rally.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Twist Bioscience Soars 5.16% Intraday After Q3 Revenue Beat, Raised FY Guidance, and EBITDA Breakeven Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Twist Bioscience Soars 5.16% Intraday After Q3 Revenue Beat, Raised FY Guidance, and EBITDA Breakeven Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-03 22:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Twist Bioscience Corp. (TWST) shares surged 5.16% during intraday trading on Monday, as investors reacted positively to the company's fiscal third-quarter 2026 earnings release, which delivered a top-line beat, raised full-year guidance, and a clear path to adjusted EBITDA breakeven.</p><p>The company reported Q3 FY26 revenue of $118.4 million, up 23% year-over-year and comfortably above the FactSet consensus estimate of $114.5 million. Gross margin improved to 52.8%, while the adjusted EBITDA loss narrowed to $11.3 million. Management also raised its full-year fiscal 2026 revenue guidance to a range of $456 million to $457 million, up from the prior $442 million to $447 million, and projected fourth-quarter revenue of approximately $123 million to $124 million, well ahead of the $117.4 million consensus.</p><p>Adding to the bullish sentiment, Twist Bioscience said it expects to achieve adjusted EBITDA breakeven in the fiscal fourth quarter and sees full-year gross margins above 52%. The combination of accelerating revenue growth, margin expansion, and a near-term profitability milestone fueled the sharp intraday rally.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TWST","symbol_name":"Twist Bioscience Corp","start_time":0,"source_url":"","article_id":"1198645126","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198645126","pubTimestamp":1785766239,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Twist Bioscience Corp. (TWST) shares surged 5.16% during intraday trading on Monday, as investors reacted positively to the company's fiscal third-quarter 2026 earnings release, which delivered a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TWST":"Twist Bioscience Corp"},"translate_title":"股票跟踪 | 第三季度收入超出预期、上调财年指引和 EBITDA 盈亏平衡前景后，Twist Bioscience 盘中飙升 5.16%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TWST":1},"content_text":"Twist Bioscience Corp. (TWST) shares surged 5.16% during intraday trading on Monday, as investors reacted positively to the company's fiscal third-quarter 2026 earnings release, which delivered a top-line beat, raised full-year guidance, and a clear path to adjusted EBITDA breakeven.The company reported Q3 FY26 revenue of $118.4 million, up 23% year-over-year and comfortably above the FactSet consensus estimate of $114.5 million. Gross margin improved to 52.8%, while the adjusted EBITDA loss narrowed to $11.3 million. Management also raised its full-year fiscal 2026 revenue guidance to a range of $456 million to $457 million, up from the prior $442 million to $447 million, and projected fourth-quarter revenue of approximately $123 million to $124 million, well ahead of the $117.4 million consensus.Adding to the bullish sentiment, Twist Bioscience said it expects to achieve adjusted EBITDA breakeven in the fiscal fourth quarter and sees full-year gross margins above 52%. The combination of accelerating revenue growth, margin expansion, and a near-term profitability milestone fueled the sharp intraday rally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1198645126","isCrawlerRequest":true}